Physician profile
John Gregory Cooper
NPI 1740229939
$5,138.53
in general payments reported to CMS, 2019-2025
41 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $906 · 2021: $1,058 · 2022: $854 · 2023: $316 · 2024: $707 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $640.35 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $404.58 | 2019-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $393.53 | 2019-2024 | |
| Lilly USA, LLC | $281.11 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $275.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.19 | 2019-2025 | Xifaxan |
| Abbvie INC. | $250.96 | 2021-2025 | |
| Astellas Pharma US INC | $236.25 | 2019-2021 | |
| Novo Nordisk INC | $222.59 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $212.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.60 | 2022-2025 | |
| Amarin Pharma, INC. | $187.62 | 2019-2021 | |
| Axsome Therapeutics, INC. | $170.44 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $167.22 | 2021-2025 | Verquvo, Steglatro, Gardasil 9 |
| Allergan, INC. | $148.48 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.